ESSA Pharma Inc. (EPIX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Vancouver, BC, Canada. El CEO actual es David Ross Parkinson.
EPIX tiene fecha de IPO 2015-03-13, 35 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $9.52M.
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
